报价延迟最少15分钟:2026/04/15 13:33 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.36 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.76/-2.44
|
|
企业价值
545.22M
|
| 资产负债 |
|
每股账面净值
1.99
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
170.44M
|
|
每股收益
1.88
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeuticproteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases. |
